Potential Serological Biomarkers of Cerebral Malaria

Biomarkers have been used to diagnose and prognosticate the progress and outcome of many chronic diseases such as neoplastic and non communicable diseases. However, only recently did the field of malaria research move in the direction of actively identifying biomarkers that can accurately discrimina...

Full description

Bibliographic Details
Main Authors: Naomi W. Lucchi, Vidhan Jain, Nana O. Wilson, Neeru Singh, Venkatachalam Udhayakumar, Jonathan K. Stiles
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.3233/DMA-2011-0854
id doaj-e63f4ad03f2a4ba386eb5ce295c521b0
record_format Article
spelling doaj-e63f4ad03f2a4ba386eb5ce295c521b02020-11-24T21:59:52ZengHindawi LimitedDisease Markers0278-02401875-86302011-01-0131632733510.3233/DMA-2011-0854Potential Serological Biomarkers of Cerebral MalariaNaomi W. Lucchi0Vidhan Jain1Nana O. Wilson2Neeru Singh3Venkatachalam Udhayakumar4Jonathan K. Stiles5Atlanta Research and Education Foundation, Decatur, GA, USANational Institute of Malaria Research, Regional Medical Research Center for Tribals, Jabalpur, IndiaMorehouse School of Medicine, Atlanta, GA, USANational Institute of Malaria Research, Regional Medical Research Center for Tribals, Jabalpur, IndiaAtlanta Research and Education Foundation, Decatur, GA, USAMorehouse School of Medicine, Atlanta, GA, USABiomarkers have been used to diagnose and prognosticate the progress and outcome of many chronic diseases such as neoplastic and non communicable diseases. However, only recently did the field of malaria research move in the direction of actively identifying biomarkers that can accurately discriminate the severe forms of malaria. Malaria continues to be a deadly disease, killing close to a million people (mostly children) every year. One life-threatening complication of malaria is cerebral malaria (CM). Studies carried out in Africa have demonstrated that even with the best treatment, as high as 15–30% of CM patients die and about 10–24% of CM survivors suffer short-or long-term neurological impairment. The transition from mild malaria to CM can be sudden and requires immediate intervention. Currently, there is no biological test available to confirm the diagnosis of CM and its complications. It is hoped that development of biomarkers to identify CM patients and potential risk for adverse outcomes would greatly enhance better intervention and clinical management to improve the outcomes. We review here what is currently known regarding biomarkers for CM outcomes.http://dx.doi.org/10.3233/DMA-2011-0854
collection DOAJ
language English
format Article
sources DOAJ
author Naomi W. Lucchi
Vidhan Jain
Nana O. Wilson
Neeru Singh
Venkatachalam Udhayakumar
Jonathan K. Stiles
spellingShingle Naomi W. Lucchi
Vidhan Jain
Nana O. Wilson
Neeru Singh
Venkatachalam Udhayakumar
Jonathan K. Stiles
Potential Serological Biomarkers of Cerebral Malaria
Disease Markers
author_facet Naomi W. Lucchi
Vidhan Jain
Nana O. Wilson
Neeru Singh
Venkatachalam Udhayakumar
Jonathan K. Stiles
author_sort Naomi W. Lucchi
title Potential Serological Biomarkers of Cerebral Malaria
title_short Potential Serological Biomarkers of Cerebral Malaria
title_full Potential Serological Biomarkers of Cerebral Malaria
title_fullStr Potential Serological Biomarkers of Cerebral Malaria
title_full_unstemmed Potential Serological Biomarkers of Cerebral Malaria
title_sort potential serological biomarkers of cerebral malaria
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2011-01-01
description Biomarkers have been used to diagnose and prognosticate the progress and outcome of many chronic diseases such as neoplastic and non communicable diseases. However, only recently did the field of malaria research move in the direction of actively identifying biomarkers that can accurately discriminate the severe forms of malaria. Malaria continues to be a deadly disease, killing close to a million people (mostly children) every year. One life-threatening complication of malaria is cerebral malaria (CM). Studies carried out in Africa have demonstrated that even with the best treatment, as high as 15–30% of CM patients die and about 10–24% of CM survivors suffer short-or long-term neurological impairment. The transition from mild malaria to CM can be sudden and requires immediate intervention. Currently, there is no biological test available to confirm the diagnosis of CM and its complications. It is hoped that development of biomarkers to identify CM patients and potential risk for adverse outcomes would greatly enhance better intervention and clinical management to improve the outcomes. We review here what is currently known regarding biomarkers for CM outcomes.
url http://dx.doi.org/10.3233/DMA-2011-0854
work_keys_str_mv AT naomiwlucchi potentialserologicalbiomarkersofcerebralmalaria
AT vidhanjain potentialserologicalbiomarkersofcerebralmalaria
AT nanaowilson potentialserologicalbiomarkersofcerebralmalaria
AT neerusingh potentialserologicalbiomarkersofcerebralmalaria
AT venkatachalamudhayakumar potentialserologicalbiomarkersofcerebralmalaria
AT jonathankstiles potentialserologicalbiomarkersofcerebralmalaria
_version_ 1725846877658677248